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Thioredoxin  reductase  (TrxR) isoforms  play  important  roles  in  cell  physiology,  protecting  cells against
oxidative  processes.  In addition  to its endogenous  substrates  (Trx  isoforms),  hepatic  TrxR  can  reduce
organic  selenium  compounds  such  as ebselen  and  diphenyl  diselenide  to  their  selenol  intermediates,
which  can  be involved  in their  hepatoprotective  properties.  Taking  this  into  account,  the  aim  of  the
present  study  was  to  evaluate  the  hypothesis  that  ebselen,  diphenyl  diselenide  and  its  analogs  (4,4′-
bistriﬂuoromethyldiphenyl  diselenide,  4,4′-bismethoxydiphenyl  diselenide,  4.4′-biscarboxy-diphenyl
diselenide,  4,4′-bischlorodiphenyl  diselenide,  2,4,6,2′,4′,6′-hexamethyldiphenyl  diselenide)  could  be  sub-
strates  of rat  brain  TrxR.  In  the  presence  of  partially  puriﬁed  rat  brain  TrxR,  diphenyl  diselenide,
bismethoxydiphenyl  diselenide  and  bischlorodiphenyl  diselenide  (at 10,  15 and  20 M) stimulated
NADPH  oxidation,  indicating  that  they  are substrates  of brain  TrxR.  In  contrast,  ebselen and  bistriﬂu-
oromethyldiphenyl  diselenide,  that  have  been  previously  demonstrated  to  be  substrate  of  hepatic  TrxR,
were  not  reduced  by  rat brain  TrxR. The  results  presented  here  suggest  that  diphenyl  diselenide  can  exert
neuroprotective  effects  by  mimicking  glutathione  peroxidase  activity  and  also  via its reduction  by  TrxR.
However,  ebselen  was  not  reduced  by brain  TrxR,  indicating  that the  neuroprotective  properties  of  this
compound  is  possibly  mediate  by  its glutathione  peroxidase-like  activity.xidation is a fundamental part of life and aerobic metabolism.
owever, excessive free radicals production, as well as low antiox-
dant defenses can be harmful to living cell. In effect, reactive
xygen and nitrogen species can oxidize macromolecules (protein,
NA, lipids and carbohydrates), which can lead to cell dysfunc-
ion. Therefore, oxidative stress can be involved in the development
f chronic degenerative diseases, including neurological diseases
4,10,12,15,24]. Of particular pharmacological signiﬁcance, exper-
mental studies have indicated that antioxidants may  reduce
xidative damage associated with different pathological conditions
2,3,7,20].
Selenium (Se) is an integral component of about 25 seleno-
roteins, including critical antioxidant seleno-enzymes; namely,
he isoforms of glutathione peroxidase (GPx) and thioredoxin
eductase (TrxR) [1,13,19,21,23]. Selenium is normally found as a
elenocysteine residue and its selenol group is a softer and stronger
ucleophile than its sulfur (cysteine) analog. Consequently, the
elenol group is expected to attack toxic electrophile species more
fﬁciently than thiol analogs [8,9,19]. Maintenance of full GPx and
rxR activity by adequate dietary selenium supply has been pro-
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posed to be useful for the prevention of several cardiovascular and
neurological disorders [23].
Of particular therapeutic signiﬁcance, organoselenium com-
pounds can mimicry endogenous antioxidant enzymes, such as
GPx or can be metabolized by TrxR to form selenol intermedi-
ates [6,16,25,26] that can imitate the function of the antioxidant
selenoenzymes [14,18,19]. For instance, ebselen and diphenyl dis-
elenide have antioxidant, anti-inﬂammatory and neuroprotective
properties [16–20,22] that can be mediated, at least in part, by their
in vivo metabolism to selenol intermediates [18,19].
Recently we  have demonstrated that diphenyl diselenide and
some analogs are substrates of rat liver mammalian TrxR [6],
which is in accordance with previous studies from the labora-
tory of Holmgren [25,26], which has demonstrated that ebselen
and its diselenide were good substrates of Escherichia coli, human
placenta and calf thymus TrxR. Of potential pharmacological sig-
niﬁcance, the reduction of these substrates by mammalian TrxR
isoforms can generate selenol intermediates that could imitate
the role of some antioxidant selenoenzymes, such as GPx and
TrxR [6]. In effect, Holmgren and collaborators have indicated
that the TrxR-like (i.e., the ability of TrxR to form the selenol
Open access under the Elsevier OA license.intermediate of ebselen) is more important than the glutathione
peroxidase-like activity of ebselen [25,26]. In analogy, the ben-
eﬁcial effects of diphenyl diselenide and its analogs can also
be mediated via their reduction catalyzed by the liver TrxR [6].
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owever, to the best of our knowledge, the potential reduction
f diphenyl diselenide and ebselen by cerebral TrxR enzymes
as not been previously investigated. In effect, the reduction of
bselen (or its diselenide) and of diphenyl diselenide by brain
rxR can be an important molecular mechanism involved in
heir neuroprotective properties. We  therefore aimed to evaluate
he hypothesis that diphenyl diselenide and its analogs (4,4′-
istriﬂuoromethyl-diphenyl diselenide, 4,4′-bismethoxy-diphenyl
iselenide, 4,4′-biscarboxy-diphenyl diselenide, 4,4′-bischloro-
iphenyl diselenide, 2,4,6,2′,4′,6′-hexamethyl-diphenyl diselenide)
Fig. 1) could be substrates for rat brain TrxR. Furthermore, we  have
one a comparative study with ebselen, a prototype organosele-
ium compound that has been used in clinical trials with borderline
uccess [5,18,19,22].
All Chemicals were of analytical grade and were obtained from
igma Aldrich, Merk or Fluka. TrxR from rat brain was puriﬁed
ssentially as described by Hill et al., 1997 [11].
TrxR activity was determined according Zhao and Holmgren,
002 [25]. Activity was performed in a buffer containing 50 mM
ris–HCl, 1 mM EDTA, pH 7.5, 100 L of TrxR (8–10 g protein/mL)
nd 100 M of NADPH. The quantity of enzyme was chosen based
n previous experiments, in which trials were conducted with con-
entrations of 2.5, 5.0, 7.5, 10, 12.5, 15.0 and 20 g of the partially
uriﬁed protein/mL of reaction medium and we have observed a
inear reaction from 5.0 to 12.5 g/ml when diphenyl diselenide
nd 4,4′-bischloro-diphenyl diselenide were used as substrate (data
ot shown). Enzyme reaction was started with the addition of
rganoselenium compounds. Since ebselen and bistriﬂuoromethyl
iselenide did not stimulate NADPH oxidation in the presence of
rain TrxR, we also tested concentrations of 2.5, 5, 7.5, 30 and 50 M
data not shown).Statistical analysis were performed using three-way (type of
ompound) × (concentration) × time ANOVA. Univariate analyses
ollowed by Duncan’s multiple range test were performed where
ppropriate.compounds and ebselen.
In the presence of partially puriﬁed brain mammalian Trx
Reductase (TrxR), diphenyl diselenide, bismethoxydiphenyl dis-
elenide and bischlorodiphenyl diselenide (at 10, 15 and 20 M)
stimulated NADPH oxidation, indicating that they are substrates
of brain rat TrxR (Fig. 2A, C and E). However, ebselen and bistri-
ﬂuoromethyl diselenide did not stimulate NADPH oxidation in the
presence of partially puriﬁed rat brain TrxR. Consequently, ebselen
and bistriﬂuoromethyl diselenide are not substrate of cerebral TrxR
obtained from rats (Fig. 2B and G).
Here we  have investigated the ability of diphenyl diselenide
and its analogs (4,4′-bistriﬂuoromethyl-diphenyl diselenide,
4,4′-bismethoxy-diphenyl diselenide, 4,4′-biscarboxy-diphenyl
diselenide, 4,4′-bischloro-diphenyl diselenide, 2,4,6,2′,4′,6′-
hexamethyl-diphenyl diselenide) and ebselen to serve as
substrate of rat cerebral and hepatic TrxR enzymes. Of note,
in our recent study [6],  we  observed that diphenyl diselenide, 4,4′-
bistriﬂuoromethyl-diphenyl diselenide, 4,4′-bismethoxy-diphenyl
diselenide, 4,4′-bischloro-diphenyl diselenide and ebselen were
substrate of hepatic TrxR; in contrast, here we have observed
that ebselen and bistriﬂuoromethyl-diphenyl diselenide were
not reduced by cerebral TrxR. The differential expression of TrxR
isoforms and the existence of alternative splice variants of TrxR
in different mammalian tissues or cells [1] could explain, at least
in part, why  ebselen and bistriﬂuoromethyl-diphenyl diselenide
were not substrate of rat brain TrxR.
In accordance with our previous results [6],  here we have con-
ﬁrmed that ebselen is substrate of rat hepatic TrxR and stimulated
NADPH oxidation (Table 1). Furthermore, as previously observed
[6],  diphenyl diselenide was  six times more active than ebselen
as a substrate of hepatic TrxR (Table 1). The results presented
here suggest that diphenyl diselenide could exhibit neuroprotec-
tive properties by mimicking the activity of glutathione peroxidase
and also via its reduction catalyzed by rat brain TrxR enzymes
(Scheme 1A). However, ebselen was  not a good substrate of rat
brain TrxR, indicating that its neuroprotective properties can be
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Fig. 2. Reduction of diphenyl diselenide compounds and ebselen I (A), II (B), III (C), IV (D), V (E), VI (F), and VII (G) by cerebral mammalian thioredoxin reductase (TrxR). Enzyme
was  mixed with a medium containing 50 mM Tris–HCl, 1 mM EDTA, pH 7.5 and then the reaction was  started by adding NADPH (ﬁnal concentration 100 M).  0 M (),
10  M (©), 15 M (), and 20 M () of diselenide compounds or ebselen. Statistical analyses were performed by three-way ANOVA (7 compounds × 4 concentrations × 12
time  points). Data analysis yielded a signiﬁcant type of compound × concentration × time interaction F(180, 1680) = 11.7; p < 0.000001, which indicates that the consumption
of  NADPH was  dependent on the concentration, on the type of compound and on the sampling time.
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Scheme 1. Mechanisms for neuroprotective (A and C) and hepatoprotective (B and D) effects of diphenyl diselenide (PhSeSePh) and Ebselen (Ebse). Two pathways are
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sndicated: (1) indicates the TrxR catalyzed formation of selenophenol (the selenol
eH  (D). (2) Indicates the thiol-peroxidase-like pathway, where endogenous reduc
ntermediates (A–D).
ssociated predominantly with its thiol peroxidase-like activity
Scheme 1C). In contrast, the hepatoprotective effect of both com-
ounds can occur via the two pathways (Scheme 1B and 1D).
owever, the extent of operation of GPx-like or the TrxR-like
i.e., the NADPH reduction of ebselen or diphenyl diselenide cat-
lyzed by TrxR) pathway in vivo is unknown. Consequently, a
etter understanding of the antioxidant properties and, the poten-
ial pharmacological and therapeutic use of these agents could be
reatly improved with the determination of the extent that each
athway works in different tissues.
able 1
omparative Reduction of Diphenyl diselenide and Ebselen by Hepatic and Cerebral
rxR.
Abs 340 nm (NADPH
oxidation/min) × 103
Control Diphenyl
diselenide
Ebselen
Liver 1.00 ± 0.57 86.00 ± 4.91 14.31 ± 0.70
Brain 1.05 ± 0.14 11.60 ± 0.80 0.60 ± 0.05
ata are expressed as mean ± SEM for 3 independent experiments. Two-way
NOVA (2 (tissues: liver or brain) × 3 (compounds: control, diselenide or ebse-
en) yielded a signiﬁcant main effect of tissues (F(1,12) = 307.4; p < 0.001), main
ffect of compounds (F(2,12) = 323.6; p < 0.001), and a signiﬁcant interaction tis-
ues × compounds (F(2,12) = 188.5; p < 0.001).ediate of diphenyl diselenide, PhSeH (A and B) and the selenol of ebselen, Ebse-
ols can directly reduce diphenyl diselenide and ebselen to their respective selenol
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